Sign In
Buy SANA
$3.13
-0.120 (-3.69%)
At Close: Jul 31, 2026
Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $8.00
01:31am, Friday, 27'th Mar 2026
Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports. O
Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript
04:52am, Wednesday, 18'th Mar 2026
Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript
Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
01:46pm, Friday, 06'th Mar 2026
Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
04:05pm, Tuesday, 03'rd Mar 2026
Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evad
Sana Biotechnology to Present at March 2026 Investor Conferences
04:05pm, Monday, 23'rd Feb 2026
SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
11:51am, Friday, 20'th Feb 2026
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
Sana Biotechnology: A Small, Speculative Play
03:24am, Friday, 13'th Feb 2026
Sana Biotechnology pivots to focus on its SC451 hypoimmune cell therapy for type 1 diabetes, aiming for a functional cure. Recent single-patient data validate SANA's immune-evasion technology, driving
Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of “Moderate Buy” from Analysts
04:09am, Monday, 02'nd Feb 2026
Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One equi
Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know
01:00pm, Friday, 30'th Jan 2026
Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet
10:55am, Friday, 23'rd Jan 2026
The consensus price target hints at a 74.2% upside potential for Sana (SANA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev
Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips
07:40am, Monday, 19'th Jan 2026
SANA's thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset. SC451's planned 2026 IND is the primary catalyst goi
Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:26pm, Wednesday, 14'th Jan 2026
Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:26pm, Wednesday, 07'th Jan 2026
SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca
Sana Biotechnology (NASDAQ:SANA) Trading 7.4% Higher Following Analyst Upgrade
01:28am, Wednesday, 07'th Jan 2026
Shares of Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) rose 7.4% on Tuesday after Bank of America raised their price target on the stock from $6.00 to $7.00. Bank of America currently has
Three Genomics Stocks Worth Tracking This Year
08:11am, Tuesday, 06'th Jan 2026
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
